Popular Articles

Addition Of Anaesthetic To Radioisotope Injection Reduces Pain In Patients Undergoing Sentinel Lymph Node Mapping For Breast Cancer
The addition of the anaesthetic lidocaine to radiocolloid injection for sentinel- lymph-node (SLN) mapping in patients with early breast cancer reduces injection pain and improves patient comfort without compromising SLN identification, and should be introduced as standard practice, concludes an Article published Online First and in the September edition of The Lancet Oncology.
generic viagra online
New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate And Treatment Failure In Patients With Chronic ITP
Amgen Inc. (Nasdaq: AMGN) today released the results of a new study comparing Nplate(R) (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterised by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events. The study results show Nplate significantly reduced the incidences of splenectomy and treatment failures in non-splenectomised adult patients with chronic ITP when compared to medical SOC. The results were presented today as an oral presentation at the 14th congress of the European Hematology Association (EHA abstract #1672).
News of the day
MAP Pharmaceuticals Phase 3 Trial Of Levadex™ Migraine Product Candidate Meets All Four Primary Endpoints
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX™ orally inhaled migraine therapy met all four primary endpoints. Additional endpoints showed that LEVADEX provided rapid and sustained pain relief for up to 48 hours after dosing.
Oncology

Therapeutic Contact Lenses And Patients' Own Stem Cells Used To Rehabilitate Damaged Eye Surfaces

In a world-first breakthrough, University of New South Wales (UNSW) medical researchers have used stem cells cultured on a simple contact lens to restore sight to sufferers of blinding corneal disease. Sight was significantly improved within weeks of the procedure, which is simple, inexpensive and requires a minimal hospital stay. The research team from UNSW"s School of Medical Sciences harvested stem cells from patients" own eyes to rehabilitate the damaged cornea. The stem cells were cultured on a common therapeutic contact lens which was then placed onto the damaged cornea for 10 days, during which the cells were able to re-colonise the damaged eye surface. While the novel procedure was used to rehabilitate damaged corneas, the researchers say it offers hope to people with a range of blinding eye conditions and could have applications in other organs. A paper detailing the breakthrough appears in the high-impact journal Transplantation this week. The trial was conducted on three patients; two with extensive corneal damage resulting from multiple surgeries to remove ocular melanomas, and one with the genetic eye condition aniridia. Other causes of cornea damage can include chemical or thermal burns, bacterial infection and chemotherapy. "The procedure is totally simple and cheap," said lead author of the study, UNSW"s Dr Nick Di Girolamo. "Unlike other techniques, it requires no foreign human or animal products, only the patient"s own serum, and is completely non-invasive. "There"s no suturing, there is no major operation: all that"s involved is harvesting a minute amount - less than a millimeter - of tissue from the ocular surface," Dr Di Girolamo said. "If you"re going to be treating these sorts of diseases in third world countries all you need is the surgeon and a lab for cell culture. You don"t need any fancy equipment." Because the procedure uses the patient"s own stem cells harvested from their eye, it is ideal for sufferers of unilateral eye disease. However, it also works in patients who have had both eyes damaged, Dr Di Girolamo said. "One of our patients had aniridia, a congenital condition affecting both eyes. In that case, instead of taking the stem cells from the other cornea, we took them from another part of the eye altogether - the conjunctiva - which also harbours stem cells. "The stem cells were able to change from the conjunctival phenotype to a corneal phenotype after we put them onto the cornea. That"s the beauty of stem cells," Dr Di Girolamo said. The therapeutic contact lens used in the trial was of a type commonly used worldwide after ocular surface surgery. However, of the several brands on the market, only one was suitable for growing the stem cells. "We don"t know why. It"s probably to do with the components the manufacturers have used in that particular lens," Dr Di Girolamo said. The researchers are hopeful the technique can be adapted for use in other parts of the eye, such as the retina, and even in other organs. "If we can do this procedure in the eye, I don"t see why it wouldn"t work in other major organs such as the skin, which behaves in a very similar way to the cornea," Dr Di Girolamo said. Dr Di Girolamo"s team included UNSW medical scientists Professor Denis Wakefield and Dr Stephanie Watson. Steve Offner University of New South Wales


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):